Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.64 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.64 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28436522 | 1.00 | PTGER4 (0.64) | PTGER4PTGER2PTGER3KCNH2PTGER1 | |
| SCHEMBL16819140 | 0.84 | PTGER4 (0.51) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15587107 | 0.84 | PTGER4 (0.51) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL18942727 | 0.82 | PTGER4 (0.56) | PTGER4PTGER2PTGER3KCNH2PTGS1 | |
| SCHEMBL18943127 | 0.81 | PTGER4 (0.73) | PTGER4PTGER2PTGER3KCNH2PTGS1 | |
| SCHEMBL28427873 | 0.81 | PTGER4 (0.52) | PTGER4PTGER2PTGER3KCNH2PTGS1 | |
| SCHEMBL28427872 | 0.81 | PTGER4 (0.52) | PTGER4PTGER2PTGER3KCNH2PTGS1 | |
| SCHEMBL18123934 | 0.79 | PTGER4 (1.00) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL18123935 | 0.79 | PTGER4 (1.00) | PTGER4PTGER2PTGER3KCNH2 | |
| SCHEMBL15549258 | 0.79 | PTGER4 (1.00) | PTGER4PTGER2PTGER3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107802623-B | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | 开曼化学股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-106748951-B | Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions | 开曼化学股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3021879-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | Cayman Chemical Company, Incorporated (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |